MedPath

Docetaxel and Cisplatin With or Without Dimesna in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Phase 2
Completed
Conditions
Anemia
Drug/Agent Toxicity by Tissue/Organ
Lung Cancer
Neutropenia
Interventions
Biological: darbepoetin alfa
Biological: pegfilgrastim
Registration Number
NCT00077311
Lead Sponsor
Alliance for Clinical Trials in Oncology
Brief Summary

RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Chemoprotective drugs, such as dimesna, may help prevent or decrease the side effects (such as nerve, kidney, and inner ear damage) caused by chemotherapy.

PURPOSE: This randomized phase II trial is studying giving docetaxel and cisplatin together with dimesna to see how well it works compared to giving docetaxel and cisplatin alone in treating patients with stage IIIB or stage IV non-small cell lung cancer.

Detailed Description

OBJECTIVES:

Primary

* Compare the incidence and severity of peripheral neuropathy in patients with stage IIIB or IV non-small cell lung cancer treated with docetaxel and cisplatin with or without dimesna.

* Compare the feasibility of these regimens, in terms of febrile neutropenia and treatment delays, in these patients.

* Compare the objective response rate in patients treated with these regimens.

Secondary

* Compare the survival and failure-free survival of patients treated with these regimens.

* Compare the toxicity profile of these regimens in these patients.

* Compare the incidence and severity of cisplatin-induced nephrotoxicity in patients treated with these regimens.

OUTLINE: This is a randomized, multicenter study. Patients are randomized to 1 of 2 treatment arms.

* Arm I\*: Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour on day 1 and pegfilgrastim subcutaneously (SC) on day 2.

* Arm II\*: Patients receive docetaxel, cisplatin, and pegfilgrastim as in arm I and dimesna IV over 30 minutes on day 1.

NOTE: \*In both arms, darbepoetin alfa is administered SC on day 1 of each course for hemoglobin ≤ 11 g/dL.

In both arms, treatment repeats every 2 weeks for a total of 6 courses in the absence of disease progression or unacceptable toxicity.

Patients are followed every 3 months for 1 year and then every 6 months for 2 years.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
160
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Chemotherapy without BNP7787docetaxelChemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
Chemotherapy + BNP7787BNP7787Chemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
Chemotherapy + BNP7787darbepoetin alfaChemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
Chemotherapy + BNP7787pegfilgrastimChemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
Chemotherapy + BNP7787cisplatinChemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
Chemotherapy without BNP7787darbepoetin alfaChemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
Chemotherapy without BNP7787pegfilgrastimChemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
Chemotherapy + BNP7787docetaxelChemotherapy with dose-dense docetaxel and cisplastin with pegfilgrastim and darbepoetin with the addition of BNP7787
Chemotherapy without BNP7787cisplatinChemotherapy with dose-dense docetaxel and cisplatin with pegfilgrastim and darbepoetin for pts with NSCLC
Primary Outcome Measures
NameTimeMethod
Toxicity12 weeks

Toxicity profile w/ emphasis on incidence and severity of peripheral neuropathy, febrile neutropenia, and nephrotoxicity

Secondary Outcome Measures
NameTimeMethod
Survivalq 6 mon for 2 yrs after registration, then annually
Responseduring tx,q 3 mon for 1 yr, then q 6 mon for 2 yrs

Trial Locations

Locations (64)

Graham Hospital

🇺🇸

Canton, Illinois, United States

Greenebaum Cancer Center at University of Maryland Medical Center

🇺🇸

Baltimore, Maryland, United States

Veterans Affairs Medical Center - Baltimore

🇺🇸

Baltimore, Maryland, United States

CCOP - Hematology-Oncology Associates of Central New York

🇺🇸

Syracuse, New York, United States

University of Chicago Cancer Research Center

🇺🇸

Chicago, Illinois, United States

Galesburg Cottage Hospital

🇺🇸

Galesburg, Illinois, United States

CCOP - Illinois Oncology Research Association

🇺🇸

Peoria, Illinois, United States

Oncology/Hematology Associates of Central Illinois, P.C.

🇺🇸

Peoria, Illinois, United States

Holden Comprehensive Cancer Center at University of Iowa

🇺🇸

Iowa City, Iowa, United States

St. Joseph Medical Center

🇺🇸

Bloomington, Illinois, United States

McDonough District Hospital

🇺🇸

Macomb, Illinois, United States

Illinois Valley Community Hospital

🇺🇸

Peru, Illinois, United States

Galesburg Clinic

🇺🇸

Galesburg, Illinois, United States

Perry Memorial Hospital

🇺🇸

Princeton, Illinois, United States

Missouri Baptist Cancer Center

🇺🇸

St. Louis, Missouri, United States

Kewanee Hospital

🇺🇸

Kewanee, Illinois, United States

Community Hospital of Ottawa

🇺🇸

Ottawa, Illinois, United States

St. Margaret's Hospital

🇺🇸

Spring Valley, Illinois, United States

Louis A. Weiss Memorial Hospital

🇺🇸

Chicago, Illinois, United States

Proctor Hospital

🇺🇸

Peoria, Illinois, United States

Hematology Oncology Associates of the Quad Cities

🇺🇸

Bettendorf, Iowa, United States

CCOP - Christiana Care Health Services

🇺🇸

Newark, Delaware, United States

Cancer Resource Center - Lincoln

🇺🇸

Lincoln, Nebraska, United States

Union Hospital Cancer Center at Union Hospital

🇺🇸

Elkton MD, Maryland, United States

Lakes Region General Hospital

🇺🇸

Laconia, New Hampshire, United States

Arch Medical Services, Incorporated at Center for Cancer Care Research

🇺🇸

Saint Louis, Missouri, United States

Veterans Affairs Medical Center - Dallas

🇺🇸

Dallas, Texas, United States

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

🇺🇸

Dallas, Texas, United States

BroMenn Regional Medical Center

🇺🇸

Normal, Illinois, United States

Cancer Treatment Center at Pekin Hospital

🇺🇸

Pekin, Illinois, United States

Elliot Regional Cancer Center

🇺🇸

Manchester, New Hampshire, United States

Faxton Regional Cancer Center

🇺🇸

Utica, New York, United States

Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University

🇺🇸

Columbus, Ohio, United States

SUNY Upstate Medical University Hospital

🇺🇸

Syracuse, New York, United States

Cancer Institute of New Jersey at the Cooper University Hospital - Voorhees

🇺🇸

Voorhees, New Jersey, United States

Community General Hospital of Greater Syracuse

🇺🇸

Syracuse, New York, United States

St. Mary's Regional Cancer Center at St. Mary's Medical Center

🇺🇸

Huntington, West Virginia, United States

Lenoir Memorial Cancer Center

🇺🇸

Kinston, North Carolina, United States

Parkland Memorial Hospital

🇺🇸

Dallas, Texas, United States

Zale Lipshy University Hospital

🇺🇸

Dallas, Texas, United States

McLeod Regional Medical Center

🇺🇸

Florence, South Carolina, United States

University Medical Center of Southern Nevada

🇺🇸

Las Vegas, Nevada, United States

CCOP - Nevada Cancer Research Foundation

🇺🇸

Las Vegas, Nevada, United States

Methodist Cancer Center at Methodist Hospital - Omaha

🇺🇸

Omaha, Nebraska, United States

Cancer Care Associates - Mercy Campus

🇺🇸

Oklahoma City, Oklahoma, United States

Creighton University Medical Center

🇺🇸

Omaha, Nebraska, United States

Duke Comprehensive Cancer Center

🇺🇸

Durham, North Carolina, United States

OSF St. Francis Medical Center

🇺🇸

Peoria, Illinois, United States

Memorial Hospital

🇺🇸

Carthage, Illinois, United States

Community Cancer Center

🇺🇸

Normal, Illinois, United States

University of Illinois Cancer Center

🇺🇸

Chicago, Illinois, United States

Veterans Affairs Medical Center - Chicago Westside Hospital

🇺🇸

Chicago, Illinois, United States

Eureka Community Hospital

🇺🇸

Eureka, Illinois, United States

El Camino Hospital

🇺🇸

Mountain View, California, United States

Beebe Medical Center

🇺🇸

Lewes, Delaware, United States

St. Francis Hospital

🇺🇸

Wilmington, Delaware, United States

Hopedale Medical Complex

🇺🇸

Hopedale, Illinois, United States

Mason District Hospital

🇺🇸

Havana, Illinois, United States

Methodist Medical Center of Illinois

🇺🇸

Peoria, Illinois, United States

Charles R. Wood Cancer Center at Glens Falls Hospital

🇺🇸

Glens Falls, New York, United States

Zimmer Cancer Center at New Hanover Regional Medical Center

🇺🇸

Wilmington, North Carolina, United States

New Hampshire Oncology-Hematology, PA - Hooksett

🇺🇸

Hooksett, New Hampshire, United States

Oncology Hematology Associates of Central Illinois - Ottawa

🇺🇸

Ottawa, Illinois, United States

Wayne Memorial Hospital, Incorporated

🇺🇸

Goldsboro, North Carolina, United States

© Copyright 2025. All Rights Reserved by MedPath